SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of biotechnology and medical devices, understanding operational efficiency is crucial. Exelixis, Inc. and MiMedx Group, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Exelixis has seen a staggering 967% increase in its Selling, General, and Administrative (SG&A) expenses, reflecting its aggressive expansion and investment in growth. In contrast, MiMedx Group's SG&A expenses grew by a more modest 133%, indicating a steadier, perhaps more conservative approach.

Exelixis's SG&A expenses surged from $50 million in 2014 to over $540 million in 2023, while MiMedx Group's expenses rose from $90 million to $211 million in the same period. This divergence highlights differing strategic priorities and market responses. Investors and analysts should consider these trends when evaluating the companies' future potential and operational strategies.